User profiles for Alberto Lleó
 | Alberto LleoNeurology Department. Hospital Sant Pau. Barcelona. Verified email at santpau.es Cited by 33057 |
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
…, F Mazaheri, S Tahirovic, A Lleó… - Science translational …, 2014 - science.org
Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have
been linked to Nasu-Hakola disease, Alzheimer’s disease (AD), Parkinson’s disease, …
been linked to Nasu-Hakola disease, Alzheimer’s disease (AD), Parkinson’s disease, …
CSF biomarker variability in the Alzheimer's Association quality control program
Background The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and
phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient …
phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient …
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
Importance Amyloid-β positron emission tomography (PET) imaging allows in vivo detection
of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its …
of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its …
sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
TREM 2 is an innate immune receptor expressed on the surface of microglia. Loss‐of‐function
mutations of TREM 2 are associated with increased risk of Alzheimer's disease ( AD ). …
mutations of TREM 2 are associated with increased risk of Alzheimer's disease ( AD ). …
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
…, J Avila, C Guardia-Laguarta, J Clarimón, A Lleó… - Neurobiology of …, 2009 - Elsevier
Amyloid deposits, neurofibrillary tangles, and neuronal cell death in selectively vulnerable
brain regions are the chief hallmarks in Alzheimer's (AD) brains. Glycogen synthase kinase-3 (…
brain regions are the chief hallmarks in Alzheimer's (AD) brains. Glycogen synthase kinase-3 (…
Frontotemporal dementia and its subtypes: a genome-wide association study
…, M Serpente, E Scarpini, J Clarimón, A Lleó… - The Lancet …, 2014 - thelancet.com
Background Frontotemporal dementia (FTD) is a complex disorder characterised by a broad
range of clinical manifestations, differential pathological signatures, and genetic variability. …
range of clinical manifestations, differential pathological signatures, and genetic variability. …
Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
Background Alzheimer's disease and its complications are the leading cause of death in
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …
[PDF][PDF] Synaptic oligomeric tau in Alzheimer's disease—a potential culprit in the spread of tau pathology through the brain
In Alzheimer's disease, fibrillar tau pathology accumulates and spreads through the brain
and synapses are lost. Evidence from mouse models indicates that tau spreads trans-…
and synapses are lost. Evidence from mouse models indicates that tau spreads trans-…
A multicentre validation study of the diagnostic value of plasma neurofilament light
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a …
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a …
